Recent drug use, homelessness and increased short-term mortality in HIV-infected persons with alcohol problems

AIDS

Volumn 22, Issue 3, 2008, Pages 415-420

  Walley, Alexander Y ^a,d   Cheng, Debbie M ^a,c   Libman, Howard ^b   Nunes, David ^a   Horsburgh Jr , C Robert ^c   Saitz, Richard ^a,c   Samet, Jeffrey H ^a,c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d BOSTON MEDICAL CENTER   (United States)

Author keywords

Alcohol; Cocaine; Heroin; HIV; Homeless persons; Mortality

Indexed keywords

ADULT; ALCOHOL ABUSE; ARTICLE; CD4 LYMPHOCYTE COUNT; COCAINE DEPENDENCE; DRUG ABUSE; FEMALE; HEROIN DEPENDENCE; HOMELESSNESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SURVIVAL;

ADULT; ALCOHOLISM; COCAINE-RELATED DISORDERS; COHORT STUDIES; FEMALE; HEROIN DEPENDENCE; HIV INFECTIONS; HOMELESS PERSONS; HUMANS; LONGITUDINAL STUDIES; MALE; PROPORTIONAL HAZARDS MODELS; SUBSTANCE-RELATED DISORDERS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 38149120723     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282f423f8     Document Type: Article

References (46)

1. Keiser O, Taffe P, Zwahlen M, Battegay M, Bernasconi E, Weber R, et al. All cause mortality in the Swiss HIV Cohort Study from 1990 to 2001 in comparison with the Swiss population. AIDS 2004; 18:1835-1843.
2. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
3. Detels R, Munoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998; 280:1497-1503.
4. Hogg RS, Yip B, Kully C, Craib KJ, O'Shaughnessy MV, Schechter MT, et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ 1999; 160:659-665.
5. Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001; 135:17-26.
6. Whitman S, Murphy J, Cohen M, Sherer R. Marked declines in human immunodeficiency virus-related mortality in Chicago in women, African Americans, Hispanics, young adults, and injection drug users, from 1995 through 1997. Arch Intern Med 2000; 160:365-369.
7. Vlahov D, Galai N, Safaeian M, Galea S, Kirk GD, Lucas GM, et al. Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection. Am J Epidemiol 2005; 161:999-1012.
8. Poundstone KE, Chaisson RE, Moore RD. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS 2001; 15:1115-1123.
9. Moore RD, Keruly JC, Chaisson RE. Differences in HIV disease progression by injecting drug use in HIV-infected persons in care. J Acquir Immune Defic Syndr 2004; 35:46-51.
10. Perez-Hoyos S, del Amo J, Muga R, del Romero J, Garcia de Olalla P, Guerrero R, et al. Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category. AIDS 2003; 17:353-359.
11. Smith DK, Gardner LI, Phelps R, Hamburger ME, Carpenter C, Klein RS, et al. Mortality rates and causes of death in a cohort of HIV-infected and uninfected women, 1993-1999. J Urban Health 2003; 80:676-688.
12. Centers for Disease Control and Prevention. HIV diagnoses among injection-drug users in states with HIV surveillance: 25 states, 1994-2000. MMWR Morb Mortal Wkly Rep 2003; 52:634-636.
13. Centers for Disease Control and Prevention. Trends in HIV/AIDS diagnoses: 33 states, 2001-2004. MMWR Morb Mortal Wkly Rep 2005; 54:1149-1153.
14. Petry NM. Alcohol use in HIV patients: what we don't know may hurt us. Int J STD AIDS 1999; 10:561-570.
15. Samet JH, Phillips SJ, Horton NJ, Traphagen ET, Freedberg KA. Detecting alcohol problems in HIV-infected patients: use of the CAGE questionnaire. AIDS Res Hum Retroviruses 2004; 20:151-155.
16. Smereck GA, Hockman EM. Prevalence of HIV infection and HIV risk behaviors associated with living place: on-the-street homeless drug users as a special target population for public health intervention. Am J Drug Alcohol Abuse 1998; 24:299-319.
17. Zolopa AR, Hahn JA, Gorter R, Miranda J, Wlodarczyk D, Peterson J, et al. HIV and tuberculosis infection in San Francisco's homeless adults. Prevalence and risk factors in a representative sample. JAMA 1994; 272:455-461.
18. Torres RA, Mani S, Altholz J, Brickner PW. Human immunodeficiency virus infection among homeless men in a New York City shelter. Association with Mycobacterium tuberculosis infection. Arch Intern Med 1990; 150:2030-2036.
19. Metsch LR, McCoy CB, McCoy HV, Shultz JM, Lai S, Weatherby NL, et al. HIV-related risk behaviors and seropositivity among homeless drug-abusing women in Miami, Florida. J Psychoact Drugs 1995; 27:435-446.
20. Kohli R, Lo Y, Howard AA, Buono D, Floris-Moore M, Klein RS, et al. Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 41:864-872.
21. Riley ED, Bangsberg DR, Guzman D, Perry S, Moss AR. Antiretroviral therapy, hepatitis C virus, and AIDS mortality among San Francisco's homeless and marginally housed. J Acquir Immune Defic Syndr 2005; 38:191-195.
22. Lucas GM, Griswold M, Gebo KA, Keruly J, Chaisson RE, Moore RD. Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol 2006; 163:412-420.
23. Kapadia F, Cook JA, Cohen MH, Sohler N, Kovacs A, Greenblatt RM, et al. The relationship between noninjection drug use behaviors on progression to AIDS and death in a cohort of HIV seropositive women in the era of highly active antiretroviral therapy use. Addiction 2005; 100:990-1002.
24. Samet JH, Horton NJ, Traphagen ET, Lyon SM, Freedberg KA. Alcohol consumption and HIV disease progression: are they related? Alcohol Clin Exp Res 2003; 27:862-867.
25. Libman H, Saitz R, Nunes D, Cheng DM, Richardson JM, Vidaver J, et al. Hepatitis C infection is associated with depressive symptoms in HIV-infected adults with alcohol problems. Am J Gastroenterol 2006; 101:1804-1810.
26. Buchsbaum DG, Buchanan RG, Centor RM, Schnoll SH, Lawton MJ. Screening for alcohol abuse using CAGE scores and likelihood ratios. Ann Intern Med 1991; 115:774-777.
27. Mayfield D, McLeod G, Hall P. The CAGE questionnaire: validation of a new alcoholism screening instrument. Am J Psychiatry 1974; 131:1121-1123.
28. Sobell L, Sobell M. Timeline followback: a technique for assessing self-reported alcohol consumption. In Measuring Alcohol Consumption: Psychosocial and Biological Methods. Edited by Litten RZ, Allen J. New Jersey: Humana Press; 1992. pp. 41-72.
29. Sobell L, Sobell M. Alcohol timeline followback (TLFB) Users' Manual. Toronto, Canada: Addiction Research Foundation; 1995.
30. Fals-Stewart W, O'Farrell TJ, Freitas TT, McFarlin SK, Rutigliano P. The timeline followback reports of psychoactive substance use by drug-abusing patients: psychometric properties. J Consult Clin Psychol 2000; 68:134-144.
31. Robins LN, Wing J, Wittchen HU, Helzer JE, Babor TF, Burke J, et al. The Composite International Diagnostic Interview. An epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Arch Gen Psychiatry 1988; 45:1069-1077.
32. Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000; 12:255-266.
33. Delate T, Coons SJ. The discriminative ability of the 12-item Short Form Health Survey (SF-12) in a sample of persons infected with HIV. Clin Ther 2000; 22:1112-1120.
34. Viswanathan H, Anderson R, Thomas J 3rd. Nature and correlates of SF-12 physical and mental quality of life components among low-income HIV adults using an HIV service center. Qual Life Res 2005; 14:935-944.
35. Kalichman SC, Rompa D, Cage M. Distinguishing between overlapping somatic symptoms of depression and HIV disease in people living with HIV-AIDS. J Nerv Ment Dis 2000; 188:662-670.
36. Radloff L. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Measure 1977; 1:385-401.
37. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
38. Green CA, Polen MR. The health and health behaviors of people who do not drink alcohol. Am J Prev Med 2001; 21:298-305.
39. Fillmore KM, Golding JM, Graves KL, Kniep S, Leino EV, Romelsjo A, et al. Alcohol consumption and mortality. I. Characteristics of drinking groups. Addiction 1998; 93:183-203.
40. Lum PJ, Tulsky JP. The medical management of opioid dependence in HIV primary care settings. Curr HIV/AIDS Rep 2006; 3:195-204.
41. Basu S, Smith-Rohrberg D, Bruce RD, Altice FL. Models for integrating buprenorphine therapy into the primary HIV care setting. Clin Infect Dis 2006; 42:716-721.
42. Sullivan LE, Barry D, Moore BA, Chawarski MC, Tetrault JM, Pantalon MV, et al. A trial of integrated buprenorphine/naloxone and HIV clinical care. Clin Infect Dis 2006; 43 (Suppl 4):S184-S190.
43. Rothman J, Rudnick D, Slifer M, Agins B, Heiner K, Birkhead G. Co-located substance use treatment and HIV prevention and primary care services, New York State, 1990-2002: A model for effective service delivery to a high-risk population. J Urban Health 2007; 84:226-242.
44. Clark C, Rich AR. Outcomes of homeless adults with mental illness in a housing program and in case management only. Psychiatr Serv 2003; 54:78-83.
45. Tsemberis S, Gulcur L, Nakae M. Housing First, consumer choice, and harm reduction for homeless individuals with a dual diagnosis. Am J Public Health 2004; 94:651-656.
46. Martinez TE, Burt MR. Impact of permanent supportive housing on the use of acute care health services by homeless adults. Psychiatr Serv 2006; 57:992-999.